title: Human biomarkers: can they help us to develop a new tuberculosis vaccine?
abstract: The most effective intervention for the control of infectious disease is vaccination. The BCG vaccine, the only licensed vaccine for the prevention of tuberculosis (TB) disease, is only partially effective and a new vaccine is urgently needed. Biomarkers can aid the development of new TB vaccines through discovery of immune mechanisms, early assessment of vaccine immunogenicity or vaccine take and identification of those at greatest risk of disease progression for recruitment into smaller, targeted efficacy trials. The ultimate goal, however, remains a biomarker of TB vaccine efficacy that can be used as a surrogate for a TB disease end point and there remains an urgent need for further research in this area.
authors.affiliation: London School of Hygiene & Tropical Medicine, London, W1CE 7HT, UK.
authors.forename: Helen A
authors.initials: HA
authors.lastname: Fletcher
authors.affiliation: London School of Hygiene & Tropical Medicine, London, W1CE 7HT, UK.
authors.forename: Hazel M
authors.initials: HM
authors.lastname: Dockrell
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000032:analysis*; D015195:Drug Design; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000235:genetics / Q000276:immunology*; D014376:Tuberculosis / Q000382:microbiology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014611:Vaccination
chemical_list: D015415:Biomarkers; D032581:Tuberculosis Vaccines
keywords: BCG; biomarker correlate; tuberculosis; vaccine